- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04351503
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In order to evaluate the impact of the new SARS-CoV-2 this study analyzes the clinical outcomes of patients with a confirmed SARS-CoV-2 infection using a systems approach. The objective is to integrate various datasets covering clinical and non-clinical variables. Beside host factors such as age, gender, comorbidities and treatments, microbiological factors, such as SARS-CoV-2 viral loads using a (semi)-quantitative nucleic acid test (QNAT), genome sequences, and virus-specific immune responses are included. In addition, epidemiological aspects within the city, such as case numbers in specific areas and resulting saturation of the healthcare system (e.g. patients being hospitalized, and ICU occupancy), will be analyzed. Further epidemiological data will be generated from biological measurements from all available serum and respiratory samples (leftover material) collected from February 2020 to November 2021 over two seasons as it is likely that a second wave will be circulating in the following winter 2020/2021.
In this project, three retrospective studies will be conducted:
Study A: retrospective observational case-control study to predict the clinical outcomes and features of SARS-CoV-2 infection. The clinical outcomes of SARSCoV-2 infected patients (cases) and non-SARS-CoV-2 infected patients with or without other respiratory viruses (control) will be explored.
Study B: retrospective observational epidemiological surveillance study to describe the epidemiology of the SARS-CoV-2 outbreak; description of the epidemiological spread of the new SARS-CoV-2 virus in people living in Basel.
Study C: retrospective observational viral evolution study whereby respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected. Virus genomes obtained during the expanding, peak, and contracting phase of the pandemic will be compared to identify predictors of viral evolution, viral loads, majority species, immune escape variants, and the implications for clinical outcome, diagnostic detection, treatment, and vaccine design. Correlating specifically the occurrence and rate and variants of SARS-CoV-2 re-infections in city blocks of high activity and exposure risk will be of interest.
Study D: retrospective observational treatment outcome study whereby clinical outcome, laboratory, radiological, pulmonary function and virological data as well as data on immune responses will be used to study safety and efficacy of different treatment modalities. All data and material will be collected on a routine basis during hospitalization and in the outpatient setting to assess the safety and effect of different treatment modalities on outcome.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Adrian Egli, Prof. Dr. med.
- Phone Number: +41 61 556 57 49
- Email: adrian.egli@usb.ch
Study Locations
-
-
-
Allschwil, Switzerland, 4123
- Recruiting
- Viollier AG
-
Contact:
- Diana Ciardo, Dr. med
- Phone Number: +41 61 486 11 11
- Email: diana.ciardo@viollier.ch
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital Basel
-
Contact:
- Adrian Egli, Prof. Dr. med
- Phone Number: +41 61 556 57 49
- Email: adrian.egli@usb.ch
-
Sub-Investigator:
- Roland Bingisser, Prof. Dr. med
-
Sub-Investigator:
- Andreas Buser, Prof. Dr. med
-
Sub-Investigator:
- Hans Hirsch, Prof. Dr. med.
-
Sub-Investigator:
- Hans Pargger, Prof. Dr. med
-
Sub-Investigator:
- Bram Stieltjes, Dr. med
-
Sub-Investigator:
- Sarah Tschudin- Sutter, Prof. Dr. med.
-
Basel, Switzerland, 4056
- Recruiting
- Biozentrum University of Basel
-
Contact:
- Richard Neher, Prof. Dr. med
- Phone Number: +41 61 207 58 34
- Email: richard.neher@unibas.ch
-
Basel, Switzerland, 4056
- Recruiting
- sciCore University of Basel
-
Contact:
- Thierry Sengstag, Dr.
- Phone Number: +41 61 207 18 53
- Email: thierry.sengstag@unibas.ch
-
Basel, Switzerland, 4058
- Recruiting
- Department of Biosystems Science and Engineering ETH Zurich
-
Contact:
- Karsten Borgwardt, Prof.Dr. med
- Phone Number: +41 61 387 34 20
- Email: karsten.borgwardt@bsse.ethz.ch
-
Geneva, Switzerland, 1202
- Recruiting
- Swiss Institute of Bioinformatics
-
Contact:
- Valérie Barbié, Dr. med
- Phone Number: +41 22 379 02 65
- Email: valerie.barbie@sib.swiss
-
Contact:
- Aitana Lebrand, Dr. med.
- Phone Number: +41 22 379 02 67
- Email: aitana.lebrand@sib.swiss
-
Sub-Investigator:
- Aitana Lebrand, Dr. med.
-
Sub-Investigator:
- Valérie Barbié, Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Study A: All patients being tested for SARS-CoV-2 at the University Hospital Basel (USB) and with residency in Basel (Basel-Stadt, Riehen, and Bettingen) will be included for clinical outcome evaluation. All age groups will be included. In addition, non-clinical data such as epidemiological and hospital associated data of all people living in Basel but not necessarily tested at the University Hospital Basel will be included
- Study B: Epidemiological data and serum and respiratory samples across all Age groups from people with residency in Basel (Basel-Stadt, Riehen, and Bettingen) with and without confirmed SARS-CoV-2 infection will be included
- Study C: SARS-CoV-2 viral genome analysis will be conducted from all patients tested positive for SARS-CoV-2 genome by NAT at the University Hospital Basel and living in Basel (Basel-Stadt, Riehen, and Bettingen). In addition, viral genome analysis will be conducted from all people tested positive for SARS-CoV-2 genome by NAT living in Basel by the mentioned study partners. All Age groups will be included.
- Patients with cleared SARS-CoV-2 infection coming for plasma donation will be included to describe immunological response after successfully cleared infection.
Exclusion Criteria:
- documented refusal of the general consent or an available/known written or oral statement against Research
- People, who are tested at the USB, with residency outside of Basel (Basel-Stadt, Riehen, and Bettingen)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
SARSCoV-infected patients (cases)
|
Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection.
Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed.
For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.
Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak.
The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation.
In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g.
population density, income and living space will be re-used.
Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.
Study C: data collection for viral evolution.
Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution.
No additional material will be collected.
Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment:
|
non-SARS-CoV-2 infected patients (control)
non-SARS-CoV-2 infected patients with or without other respiratory viruses (control).
|
Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection.
Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed.
For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of factors associated with (i) infection (binary, yes/no), (ii) hospitalization (binary, yes/no), (iii) requirement for ICU treatment (binary, yes/no)
Time Frame: at baseline
|
Identification of factors associated with (i) infection (binary, yes/no), (ii) hospitalization (binary, yes/no), (iii) requirement for ICU treatment (binary, yes/no)
|
at baseline
|
duration of hospitalization (in days)
Time Frame: at baseline
|
duration of hospitalization (in days)
|
at baseline
|
duration of Intensive Care Unit (ICU) stay (in days)
Time Frame: at baseline
|
duration of ICU stay (in days)
|
at baseline
|
in-hospital mortality (binary, yes/no)
Time Frame: at baseline
|
in-hospital mortality (binary, yes/no)
|
at baseline
|
Number of infected cases within the city of Basel
Time Frame: at baseline
|
Number of infected cases confirmed either by nucleic acid test (NAT) or by positive serology within the city of Basel expressed as incidence per statistical block
|
at baseline
|
whole genome sequencing to study pathogen evolution (number, type, and complexity of viral genome)
Time Frame: at baseline
|
Number, type, and complexity of viral genome variants and quasispecies identified by deep-sequencing during rise, peak, and contraction of the pandemic in patients and geographic areas.
|
at baseline
|
Identification which treatment modality is associated with adverse events (binary, yes/no)
Time Frame: at baseline
|
Identification which treatment modality is associated with adverse events (binary, yes/no)
|
at baseline
|
Identification which treatment modality is associated with pulmonary recovery (binary, yes/no)
Time Frame: after 30 and 90 days
|
Identification which treatment modality is associated with pulmonary recovery(binary, yes/no)
|
after 30 and 90 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Adrian Egli, Prof. Dr. med., Division of Clinical Bacteriology & Mycology, University Hospital Basel
Publications and helpful links
General Publications
- Sava M, Sommer G, Daikeler T, Woischnig AK, Martinez AE, Leuzinger K, Hirsch HH, Erlanger T, Wiencierz A, Bassetti S, Tamm M, Tschudin-Sutter S, Stoeckle M, Pargger H, Siegemund M, Boss R, Zimmer G, Vu DL, Kaiser L, Dell-Kuster S, Weisser M, Battegay M, Hostettler K, Khanna N. Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study. Swiss Med Wkly. 2021 Aug 10;151:w20550. doi: 10.4414/smw.2021.20550. eCollection 2021 Aug 2.
- Stange M, Mari A, Roloff T, Seth-Smith HM, Schweitzer M, Brunner M, Leuzinger K, Sogaard KK, Gensch A, Tschudin-Sutter S, Fuchs S, Bielicki J, Pargger H, Siegemund M, Nickel CH, Bingisser R, Osthoff M, Bassetti S, Schneider-Sliwa R, Battegay M, Hirsch HH, Egli A. SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event. PLoS Pathog. 2021 Mar 19;17(3):e1009374. doi: 10.1371/journal.ppat.1009374. eCollection 2021 Mar.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-00769; qu20Egli2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS Coronavirus (SARS-CoV-2) Infection
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
-
Boston UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Burnet Institute and other collaboratorsRecruitingSARS CoV 2 Infection | SARS CoV 2 VaccinationUnited States, Malawi
-
Imam Abdulrahman Bin Faisal UniversityDammam Medical Complex; Institute for Research and medical consultations (IRMC)UnknownHospitalized Patients | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) | Laboratory-confirmed SARS-CoV 2 InfectionSaudi Arabia
-
Chulalongkorn UniversityRamathibodi Hospital; Ministry of Health, Thailand; The Government Pharmaceutical... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS CoV 2 InfectionThailand
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and PreventionCompleted
-
Indiana UniversityCompletedSARS-CoV-2United States
Clinical Trials on Study A
-
Haukeland University HospitalHelse Stavanger HFRecruiting
-
Maltepe UniversityCompletedNurse-Patient Relations | Gender | Psychosocial Problem | Disaster; PersonalityTurkey
-
Center for Eye Research AustraliaRecruitingAge-related Macular Degeneration | Geographic Atrophy | Age Related Macular Degeneration | AMDAustralia
-
University of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
VASCage GmbHMedical University Innsbruck; St John of God Hospital, ViennaRecruiting
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
University College DublinUniversity College CorkCompletedFood Consumption Database AnalysisIreland
-
Istanbul University - Cerrahpasa (IUC)CompletedAsthma | Asthma in Children | Asthma Attack | Asthma AcuteTurkey
-
Ohio State UniversityUSDA North Central - Nutrition Education Center of ExcellenceCompleted
-
George Clinical Pty LtdActelion; The George InstituteCompletedTreatment Resistant Hypertension